TXG10x Genomics, Inc.

$80.64+518% 1Y

The financials

10x Genomics, Inc. by the numbers

10x Genomics, Inc. (TXG) reported revenue of $151M in Q2 2026 (quarter ended Jun 30, 2026), down 13% from the same quarter a year earlier. That came with a gross margin of 74% and net loss of $18M. For the full year FY2025, revenue was $643M (+5.2% year on year) and net income −$44M. Its largest product in Q2 2026 was Chromium Consumables at $88M, 56% of the disclosed total, well ahead of Spatial Consumables at 27%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.

10x Genomics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Revenue$151M$173M−13%
Gross profit$112M$125M−10%
Operating income−$20M$30Mto a loss
Net income−$18M$35Mto a loss
Diluted EPS−$0.14$0.28to a loss
Revenue by product, Q2 2026, as reported to the SEC
ProductRevenueShare
Chromium Consumables$88M56%
Spatial Consumables$42M27%
Service$11M6.7%
Instruments$7.7M4.8%
Spatial Instruments$4.6M2.9%
Chromium Instruments$3.1M1.9%
Licensing And Royalty$1.9M1.2%

Business segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Jun 2026Total $158.7M (-2.1%)
Service grew +26% year on yearLicensing And Royalty -93% year on year
  • Chromium Consumables$88.5Mquarter on quarter -0.50%year on year +3.1%
  • Spatial Consumables$42.3Mquarter on quarter +3.4%year on year +16%
  • Service$10.7Mquarter on quarter +21%year on year +26%
  • Instruments$7.7Mquarter on quarter -32%year on year -47%
  • Spatial Instruments$4.6Mquarter on quarter -24%year on year -48%
  • Chromium Instruments$3.1Mquarter on quarter -41%year on year -46%
  • Licensing And Royalty$1.9Mquarter on quarter +105%year on year -93%
Segment sum = 105% of reported consolidated revenue · Latest source: 10-Q filed Aug 7, 2026, SEC EDGAR
On our screens:Most shorted stocks